Compare Organon & Co. Common Stock (OGN) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs ProShares Ultra Gold ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while ProShares Ultra Gold ETF trades at $45.01 (market cap $730.54M). The key difference: Organon & Co. Common Stock is far larger — about 5× ProShares Ultra Gold ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| OGN | UGL | |
|---|---|---|
Market Cap | $3.62B | $730.54M |
Volume | 2,892,999 | 1,700,224 |
Sector | Health | Leveraged / Inverse |
52-Week High | $13.81 | $85.62 |
52-Week Low | $5.70 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
UGL is trading at $45.70, down 0.39% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights gold price volatility amid shifting Fed rate expectations and Treasury yield pressures, influencing sentiment.
The outlook remains cautious due to technical weakness and macroeconomic headwinds. Risks include persistent rate-hike uncertainty and gold market sensitivity. Investment potential hinges on future financial disclosures and gold price stabilization, but current data gaps and bearish signals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
